Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Envveno Medical Corp (NQ: NVNO )

3.055 +0.005 (+0.16%)
Streaming Delayed Price Updated: 10:10 AM EDT, Oct 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Envveno Medical Corp

< Previous 1 2 3 Next >
One-Year VenoValve(R) Data Published in Peer-Reviewed Journal, Vascular and Endovascular Surgery
- Previously announced promising results from the first-in-human study demonstrated sustained safety and effectiveness of the VenoValve at 1-year post-implantation - The VenoValve is currently being... 
From enVVeno Medical Corporation
Via AccessWire
Positive Long-Term VenoValve(R) First-in-Human Data Presented at 34th Annual Meeting of the American Venous Forum
- First-in-Human VenoValve recipients continue to benefit from VenoValve at average of 30 months post-surgery - No venous ulcer recurrences, relapses of CVI, or safety issues - Improvements in average... 
From enVVeno Medical Corporation
Via AccessWire
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 348 companies hit new 52-week lows. Significant Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
enVVeno Medical Announces ISO 13485 Certification
- Achievement of Quality Management System certification represents an important step towards commercialization IRVINE, CA / ACCESSWIRE / February 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO)... 
From enVVeno Medical Corporation
Via AccessWire
enVVeno Medical to Present at the Virtual Investor 2022 Top Picks Conference
Live video webcast presentation on Tuesday, January 25th at 1:00 PM ET IRVINE, CA / ACCESSWIRE / January 20, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company... 
From enVVeno Medical Corporation
Via AccessWire
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ /... 
From JTC Team, LLC
Via AccessWire
enVVeno Medical to Present at the Virtual Investor Roundtable Event
- Live moderated video webcast discussion with CEO Robert Berman and Marc Glickman, M.D., Senior Vice President and Chief Medical Officer of enVVeno on Tuesday, November 16th at 1:00 PM ET IRVINE, CA /... 
From enVVeno Medical Corporation
Via AccessWire
enVVeno Medical Reports Third Quarter 2021 Financial Results and Provides Corporate Update
- Quarter marked by corporate rebranding and strategic prioritization of development programs - Company executing on SAVVE U.S pivotal trial evaluating lead product, the VenoValve®, as a potential... 
From enVVeno Medical Corporation
Via AccessWire
JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast roundtable discussions with members of Management and Thought Leaders across participating... 
From JTC Team, LLC
Via AccessWire
enVVeno Medical Reports Successful Completion of First VenoValve Surgery for U.S. Pivotal Trial
- 75 Patient Trial Underway to Evaluate Safety and Efficacy of the VenoValve as a Potential Treatment for Severe Deep Venous Chronic Venous Insufficiency (CVI) - Severe CVI Impacts Approximately 2.4... 
From enVVeno Medical Corporation
Via AccessWire
enVVeno Medical Corporation Successfully Completes Rebranding
Company Now Trading Under Ticker Symbol "NVNO" IRVINE, CA / ACCESSWIRE / October 1, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of... 
From enVVeno Medical Corporation
Via AccessWire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.